Not a Lexis Advance subscriber? Try it out for free.


Mealey's IP/Tech - In Cross-Appeal Of Patent Dispute Over Biosimilars, Federal Circuit Panel Affirms

WASHINGTON, D.C. - A Federal Circuit U.S. Court of Appeals panel on Dec. 16 upheld in all respects a Delaware jury's determination that a patent covering the anemia drug "Epogen" is valid and infringed, as well as that a related patent is not infringed by a proposed biosimilar (Amgen Inc., et al., v. Hospira Inc., Nos. 2019-1067, -1102, Fed. Cir., 2019 U.S. App. LEXIS 37035).
Find full version on lexis Advance®